Original articleGenetic Influences on the Outcome of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-related Macular Degeneration
Section snippets
Study Design and Eligibility
We prospectively recruited patients from the retina clinics of The Royal Victorian Eye and Ear Hospital (RVEEH) from 2006 to 2010 for this study. Approval was obtained from the human research and ethics committee of the RVEEH. Research adhered to the tenets of the Declaration of Helsinki, and all patients provided written informed consent before participation.
Patient Selection
Our study cohort comprised consecutive, treatment-naïve patients >50 years of age with active subfoveal choroidal neovascularization
Results
Two hundred twenty-four patients met the inclusion/exclusion criteria and were recruited into this study and monitored for 12 months. Mean age ± standard deviation SD) of the patients was 78±6.6 years and mean ± SD VA at baseline was 51±16.8 ETDRS letter scores (approximate Snellen equivalent of 20/100). Mean change ± SD in VA from baseline after 12 months was 3.2±14.9 letters, and the patients received on average 6.4±2.3 injections over 12 months. Of the patients, 24.8% had predominantly
Discussion
In this study, we have shown for the first time a strong genetic association for homozygote risk alleles at SNP rs11200638 (HTRA1 promoter SNP) and SNP rs10490924 (A69S) in the LOC387715/ARMS2 gene with poor outcome of intravitreal anti-VEGF injections in treatment-naïve patients with neovascular AMD. We also found a borderline association between homozygote risk alleles at SNP rs3793917 in the LOC387715/ARMS2 gene and poor response to this treatment.
The risk alleles rs10490924 and rs11200638
Acknowledgments
The authors are grateful to Professor Bob Augusteyn for helpful discussions.
References (38)
- et al.
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial
Ophthalmology
(2012) - et al.
Susceptibility genes for age-related maculopathy on chromosome 10q26
Am J Hum Genet
(2005) - et al.
Further mapping of 10q26 supports strong association of HTRA1 polymorphisms with age-related macular degeneration
Vision Res
(2008) - et al.
HTRA1 promoter polymorphism and risk of age-related macular degeneration: a meta-analysis
Ann Epidemiol
(2009) - et al.
Polymorphisms in ARMS2 (LOC387715) and LOXL1 genes in the Japanese with age-related macular degeneration
Am J Ophthalmol
(2011) - et al.
Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration
Ophthalmology
(2011) - et al.
Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration
Am J Ophthalmol
(2009) - et al.
Molecular pathology of age-related macular degeneration
Prog Retin Eye Res
(2009) - et al.
High temperature requirement factor A1 (HTRA1) gene regulates angiogenesis through transforming growth factor-beta family member growth differentiation factor 6
J Biol Chem
(2012) - et al.
Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration
Neurobiol Aging
(2006)
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study
Ophthalmology
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
N Engl J Med
Complement factor H and age-related macular degeneration: the role of glycosaminoglycan recognition in disease pathology
Biochem Soc Trans
Complement factor H variant increases the risk of age-related macular degeneration
Science
Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration
JAMA
CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration
Nat Genet
Meta-analysis of genome scans of age-related macular degeneration
Hum Mol Genet
Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration
Nat Genet
Cited by (62)
Towards the application of precision medicine in Age-Related Macular Degeneration
2018, Progress in Retinal and Eye ResearchCitation Excerpt :Hagstrom et al., 2013; Orlin et al., 2012; Kloeckener-Gruissem et al., 2011). It is important to underline that several pharmacogenetic studies base their analysis on many anti-VEGF treatments, administrating both Ranibizumab and Bevacizumab (Abedi et al., 2013a, 2013b; Wickremasinghe et al., 2011). This kind of approach can sometimes provide misleading or unclear results, thus undermining their final interpretation.
Latest Development on Genetics of Common Retinal Diseases
2023, Asia-Pacific Journal of OphthalmologyGenetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential
2022, International Journal of Molecular Sciences
Manuscript no. 2012-1122.
Financial Disclosures: The authors have no proprietary or financial interest in any of the materials discussed in this article.
Funded by the National Health and Medical Research Council (NHMRC) project grants 590205 and 1008979, an NHMRC– Clinical Research Excellence grant 529923 - Translational Clinical Research in Major Eye Diseases, NHMRC practitioner fellowship 529905 (R.H.G.), NHMRC Senior Research Fellowship 1028444 (P.N.B.), and the Macular Vision Loss Support Society of Australia. The Centre for Eye Research Australia (CERA) receives Operational Infrastructure Support from the Victorian Government. The sponsor or funding organizations had no role in the design or conduct of this research.
- ∗
Both authors Robyn H. Guymer and Paul N. Baird contributed equally to this article.